Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin–kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

PCSK9 Inhibitor Evolocumab Significantly Reduces Adverse Cardiovascular Events When Added to Statin Therapy With No Major Safety Concerns Data from the first successfully completed dedicated outcomes ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...

Evolocumab (Repatha), a human monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, produced positive results in persons living with HIV in the BEIJERINCK study by reducing ...

WASHINGTON, DC (UPDATED)—The eagerly anticipated final results of FOURIER, a large clinical trial testing evolocumab (Repatha, Amgen) in patients with stable atherosclerotic cardiovascular disease, ...

Using evolocumab (Repatha; Amgen) to treat stable patients with atherosclerotic cardiovascular disease (ASCVD) and obesity results in a larger decrease in major adverse cardiovascular events than it ...